Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Lloyd_M._Segal
|
| gptkbp:collaboratesWith |
gptkb:Roche
gptkb:Bristol_Myers_Squibb |
| gptkbp:country |
gptkb:Canada
|
| gptkbp:focus |
precision oncology
synthetic lethality |
| gptkbp:foundedYear |
2016
|
| gptkbp:headquartersLocation |
Montreal, Quebec, Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Repare Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:IPODate |
2020
|
| gptkbp:notableProduct |
gptkb:RP-3500
gptkb:RP-6306 gptkb:camonsertib |
| gptkbp:researchArea |
oncology
DNA damage repair |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:RPTX
|
| gptkbp:website |
https://www.reparerx.com/
|
| gptkbp:bfsParent |
gptkb:Casdin_Capital
|
| gptkbp:bfsLayer |
6
|